InnoJin raises Series C, lifting total funding to ¥950M for eye-care SaMD push
What's the deal? InnoJinDealroom has a profile for this one. Try Dealroom →, a Tokyo-based university spinout, has raised a Series C round through a third-party allotment of shares, bringing its total funding to date to ¥950 million. The company builds digital medical products focused on ophthalmology, having previously closed seed, Series A, and Series B rounds.
What does it do? InnoJin combines an ophthalmology-focused online consultation platform, healthcare apps, and software as a medical device (SaMD) for diagnosing, treating, and preventing eye conditions. Patients can book, complete a questionnaire, consult, and pay via smartphone, with prescriptions shipped same-day.
What's the endgame? The company wants to build a next-generation ophthalmology infrastructure that links online and in-person care. Its model cycles disease awareness, online consultation, and referrals to partner clinics, using the resulting data to support preventive and personalised medicine.
Where's the money going? InnoJin will use the funds to expand its online consultation platform and accelerate clinical research, trials, and regulatory approval for its SaMD pipeline. The company also plans to tap its new investors' ophthalmology expertise and offline medical networks to grow the consultation business.
What's in the pipeline? InnoJin is developing three unapproved SaMD products: a smartphone app to aid hay fever treatment, an app for dry-eye diagnosis, and a VR-based amblyopia training tool for children. The VR product shows a clear image to the weaker eye and a blurred one to the stronger eye, aiming to improve treatment adherence over traditional eye-patch therapy.
Why now? Smartphone penetration in Japan has reached 90.6%, according to a 2023 government survey, while ophthalmology remains hard to deliver remotely because it needs specialist equipment and expertise. InnoJin argues this gap, plus long clinic waiting times, leaves room for a specialist digital service.
The signal: Japan's SaMD and treatment-app market is projected to reach roughly ¥285 billion by 2035. While general telemedicine is expanding, ophthalmology-specific digital platforms remain scarce — a niche InnoJin is betting it can own.
Image credit: NavyMedicine
